Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina begins Phase 1 cancer trial MRX34
Marina Biotech research and development executive vice president Richard Ho said the SMARTICLES delivery technology is advancing into another clinical development effort. "With the initiation of this trial,
Marina Biotech research and development executive vice president Richard Ho said the SMARTICLES delivery technology is advancing into another clinical development effort. "With the initiation of this trial,
MOR208’s efficacy in patients with relapsed or refractory NHL will be assessed in the open-label, multicentre trial. MorphoSys chief development officer Dr. Arndt Schottelius said MOR208 cancer program
The investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) completed the open-label, pioneer portion of the trial. Lexicon president and chief executive
DKSH provides contract sales services in both private clinics and trade channel for the antibiotic product line of GlaxoSmithKline. GlaxoSmithKline (Hong Kong) vice president and general manager Sally
The first interleukin-1 beta inhibitor is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection. Novartis Pharmaceuticals development global head Timothy Wright
A statistically significant increase in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy compared to placebo was not observed. The safety data were steady
The approval by Therapeutic Goods Administration (TGA) in Australia has triggered a $4m milestone payment to Curis, which is even eligible for sales based royalties of Roche’s Erivedge
The inhaled long-term, once-daily maintenance treatment is also indicated for the reduction of exacerbations in COPD patients with possible future episodes of exacerbations. Breo Ellipta comprises inhaled corticosteroid
IISIS-SMNRxis designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein. As per the terms of January 2012 agreement,
This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders. The partnership will incorporate Denovo’s pharmacogenomic technology into the analysis of biological samples obtained